microRNA-based predictor for diagnosis of frontotemporal dementia

Running title: miRNA biomarkers for FTD

Iddo Magen^{1,2,†}, Nancy-Sarah Yacovzada^{1,2,†}, Jason D. Warren³, Carolin Heller^{3,4}, Imogen Swift^{3,4}, Yoana Bobeva⁵, Andrea Malaspina^{5,6}, Jonathan D. Rohrer³, Pietro Fratta⁶, and Eran Hornstein^{1,2}

1 Department of Molecular Genetics, Weizmann Institute of Science, Rehovot, Israel

2 Department of Molecular Neuroscience, Weizmann Institute of Science, Rehovot, Israel

3 Dementia Research Centre, and 4 UK Dementia Research Institute, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK.

5 Centre for Neuroscience and Trauma, Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK.

6 Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, London, UK

† Equal contribution

Correspondence to: Eran Hornstein, Arnold R. Meyer Building, Room 314, Weizmann Institute of Science, Rehovot 76100, Israel, email: <u>eran.hornstein@weizmann.ac.il</u>.

Abstract word count: 150

Total word count (excluding title page, abstract, references and figure legend): 4870

No. of items (Figures, Tables, Supplementary): 5, 2, 6

References: 101

Key words: frontotemporal dementia; biomarker; microRNA; predictor; feature elimination.

1 Abstract

BACKGROUND: Frontotemporal dementia (FTD) is an early onset dementia that is diagnosed in
 ~20% of the progressive dementia cases. Heterogeneity in FTD clinical presentation too often
 delays clinical diagnosis and calls for molecular biomarkers to assist diagnosis, including cell free
 microRNAs (miRNA). However, nonlinearity in the relationship of miRNAs to clinical states and
 underpowered cohorts has limited research in this domain.
 METHODS: We initially studied a training cohort of 219 subjects (135 FTD and 84 non-

- 8 neurodegenerative controls) and then validated the results in a cohort of 74 subjects (33 FTD and
 9 41 controls).
- RESULTS: Based on cell-free plasma miRNA profiling by next generation sequencing and
 machine learning approaches, we develop a nonlinear prediction model that accurately
 distinguishes FTD from non-neurodegenerative controls in ~90% of cases.
- 13 DISCUSSION: The fascinating potential of diagnostic miRNA biomarkers might enable early-
- 14 stage detection and a cost-effective screening approach for clinical trials that can facilitate drug
- 15 development.

16 Background

17 Frontotemporal dementia (FTD) is a neurodegenerative disease that is characterized by frontal 18 and temporal lobe atrophy, and typically manifests with behavioral or language deficits ¹⁻⁴. The 19 key known genetic drivers of FTD include hexanucleotide repeat expansion in the first intron of 20 the gene chromosome 9 open reading frame 72 (C9ORF72) ^{5,6}, and mutations in the genes 21 encoding for microtubule associated protein Tau (MAPT) ⁷, Valosin-containing protein (VCP), 22 TANK-binding kinase 1 (TBK1), progranulin (GRN), charged multivesicular body protein 2B 23 (CHMP2B) and the RNA-binding protein TAR DNA-binding protein 43 (TDP-43)⁸⁻¹². Relatedly, 24 inclusions of Tau and TDP-43 are hallmarks of FTD neuropathology¹³,¹⁴.

25 FTD can be difficult to diagnose, due to heterogeneity in clinical presentation ¹. Three main 26 phenotypes of FTD are described: behavioral variant frontotemporal dementia (bvFTD), 27 characterized by changes in social behavior and conduct, semantic dementia (SD), characterized 28 by the loss of semantic knowledge, leading to impaired word comprehension and progressive 29 non-fluent aphasia (PNFA), characterized by progressive difficulties in speech production ^{1,15}. 30 Related motor variants within the FTD spectrum are corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP) ¹⁶. FTD further resides on a genetic and a clinico-31 32 pathological continuum with amyotrophic lateral sclerosis (ALS)¹⁷.

Brain imaging and several biofluid proteins have been proposed as biomarkers for FTD ¹⁸⁻⁴⁸.
Among the proteins, noticeable are neurofilament light chain (NfL), TDP-43, and phospho-tau,
amyloid beta and glial fibrillary acidic protein (GFAP). A recent study concluded that high NfL
blood levels are indicative of the intensity of neurodegeneration or the extent of the degenerated
axons in FTD ²⁶.

microRNAs (miRNAs) are a class of small, non-coding RNAs, that can be quantified in biofluids 38 39 in a massively parallel fashion, yielding fine-grained profiles ⁴⁹. miRNAs were suggested as 40 biomarkers in neurodegeneration and psychiatry ⁵⁰, and we too have shown their potential as cell-41 free biomarkers in neurodegeneration, focusing on the motor neuron diseases spinal muscular atrophy (SMA) and ALS ^{51,52}. Thus, low levels of miR-133 and miR-206 in the cerebrospinal fluid 42 (CSF) of patients with SMA, predicted clinically meaningful response to nusinersen therapy ⁵¹, 43 44 whereas low plasma levels of miR-181 predict longer survival and slower progression in patients with ALS 52. 45

46 Several studies suggested plasma or CSF miRNAs as diagnostic biomarkers for FTD⁵³⁻⁶².
47 However, initial studies of miRNAs in diagnosis of FTD were confounded by cohort size, sample

- heterogeneity biases or pre-selection of candidate miRNAs. Furthermore, these studies did not
 address the potential non-linear relationships between miRNAs in developing a predictor.
- 50 In the current study, we profiled blood plasma miRNAs, and developed miRNA-based classifier
- 51 for diagnosing FTD in a training cohort of 219 subjects, that was further validated in another cohort
- 52 of 74 subjects. We implemented an ensemble machine learning approach, to address biomarker
- 53 nonlinearity and were able to expose unrevealed disease-associated signals. We then confirmed
- 54 that these signals are similar between clinical subtypes of FTD. The diagnostic power of the study
- 55 roots from unbiased miRNA signature discovered by advanced machine learning, on a large and
- 56 heterogeneous cohort, and validation in an independent held-out cohort, according to the TRIPOD
- 57 guidelines ⁶³. Therefore, circulating miRNAs hold a fascinating potential as diagnostic biomarkers
- 58 that may shorten diagnostic delay in FTD.

59 Methods

60 Participants and Sampling

61 Demographic data of study participants are detailed in Table 1.

FTD subjects and their respective controls were enrolled in the longitudinal FTD cohort studies at UCL. Study cohort included 169 FTD patients and 56 controls. Additional controls (N=102) were obtained from the ALS biomarker study (Ethics approval 09/H0703/27) in Queen Mary Hospital, totaling 158 non-neurodegenerative controls. Controls were typically spouses or relatives of patients and were not reported to have any clinical signs of ALS or FTD. Informed consent was obtained from all participants. Study inclusion period was from 2009 to 2018.

All FTD patients were seen at the National Hospital for Neurology and Neurosurgery, a national referral center for young and genetic dementias in the UK; the clinic has high diagnostic accuracy in cases that come to post mortem; for the majority of cases seen in the clinic CSF biomarkers of amyloid and Tau are used to distinguish FTD and AD whenever there is any question over accuracy of diagnosis.

73 Blood was collected by venipuncture in EDTA tubes, and plasma was recovered from the whole

54 blood sample by centrifugation for 10 minutes at 3500 RPM at 4°C within 1 hour of sampling, and

75 stored at −80°C until RNA extraction and subsequent small RNA next generation sequencing.

76 Frozen plasma samples of FTD and controls from the UCL Biobanks were shipped to the

77 Weizmann Institute of Science for molecular analysis.

78 Study Design

79 Based on power analysis calculations, we found that 150 controls and 150 cases are sufficient to

80 obtain an ROC AUC of 0.7 with a power of 99% and a p-value of 0.0001. Phenotypic data on de-

81 identified patients was separated and blinded during steps of the molecular analysis.

82 Small RNA Next Generation Sequencing

Total RNA was extracted from plasma using the miRNeasy micro kit (Qiagen, Hilden, Germany) and quantified with Qubit fluorometer using RNA broad range (BR) assay kit (Thermo Fisher Scientific, Waltham, MA). For small RNA next generation sequencing (RNA-seq), libraries were prepared from 7.5 ng of total RNA using the QIAseq miRNA Library Kit and QIAseq miRNA NGS 48 Index IL (Qiagen), by an experimenter who was blinded to the identity of samples. Samples were randomly allocated to library preparation and sequencing in batches. Precise linear

89 guantification of miRNA is achieved by using unique molecular identifiers (UMIs), of random 12-90 nucleotide after 3' and 5' adapter ligation, within the reverse transcription primers ⁴⁹. cDNA 91 libraries were amplified by PCR for 22 cycles, with a 3' primer that includes a 6-nucleotide unique 92 index, followed by on-bead size selection and cleaning. Library concentration was determined 93 with Qubit fluorometer (dsDNA high sensitivity assay kit; Thermo Fisher Scientific, Waltham, MA) 94 and library size with Tapestation D1000 (Agilent). Libraries with different indices were multiplexed 95 and sequenced on NextSeq 500/550 v2 flow cell or Novaseq SP100 (Illumina), with 75bp single 96 read and 6bp index read. Fastg files were de-multiplexed using the user-friendly transcriptome 97 analysis pipeline (UTAP) ⁶⁴. Human miRNAs, as defined by miRBase ⁶⁵, were mapped using the GeneGlobe pipeline (https://geneglobe.giagen.com/us/analyze). We defined "true positive" 98 99 miRNAs and reduced the likelihood of considering "false positive" miRNAs, following previous 100 works on miRNA biomarkers in neurodegeneration⁵⁸ and other conditions⁶⁶⁻⁶⁸. To this end, we 101 included only miRNAs with an average UMI counts > 100 across all samples and with at least a single UMI across all samples, similar to our previous works^{51,52}. Data were further corrected for 102 103 the library preparation batch in order to reduce its potential bias, and normalized with DESeq2 104 package ⁶⁹ under the assumption that miRNA counts followed negative binomial distribution

105 **Constructing Cohorts and Restricting Age and Sex Biases**

106 We observed a younger mean age in controls (53.8±14.5, 95% CI [51.5- 56.1]) than in FTD 107 (65.6±8.4, 95% CI [64.4-67.0], Table S1). We reduced age-variance by excluding 34 participants 108 younger than 40, which reduced differences in mean age across the remaining meta-cohort of 109 293 subjects by 45%. Thus, 168 out of 169 FTD patients and 125 out of 158 non-110 neurodegenerative control samples were included in the analysis (Table S1). In order to verify 111 that a merged dataset of controls, collected in two different clinical centers, does not introduce 112 biases, we employed the t-distributed stochastic neighbor embedding (t-SNE) algorithm and 113 measured Kullback-Leibler divergence, the difference between probability distributions. In 114 addition, a higher prevalence of males was observed among FTD patients (65%) than among the 115 controls (35%). Therefore, sex and age variables were added to the prediction model as 116 covariates, in addition to the selected 13 miRNA predictors.

117 Gradient Boosted Trees for the Development of Disease Binary Classifiers

The FTD-disease binary classifier was developed using Gradient Boosting Classifier, a machinelearning algorithm that uses a gradient boosting framework. Diagnostic models were developed, validated and reported according to the TRIPOD guidelines ⁶³ (<u>https://www.tripod-</u>

5

statement.org/). Gradient Boosting trees 70,71, a decision-tree-based ensemble model, differ 121 122 fundamentally from conventional statistical techniques that aim to fit a single model using the 123 entire dataset. Such ensemble approach improves performance by combining strengths of 124 models that learn the data by recursive binary splits, such as trees, and of "boosting", an adaptive 125 method for combining several simple (base) models. At each iteration of the gradient boosting 126 algorithm, a subsample of the training data is selected at random (without replacement) from the 127 entire training data set, and then a simple base learner is fitted on each subsample. The final 128 boosted trees model is an additive tree model, constructed by sequentially fitting such base 129 learners on different subsamples. This procedure incorporates randomization, which is known to 130 substantially improve the predictor accuracy and also increase robustness. Additionally, boosted 131 trees can fit complex nonlinear relationships, and automatically handle interaction effects between 132 predictors as addition to other advantages of tree-based methods, such as handling features of 133 different types and accommodating missing data. Hence, in many cases their predictive 134 performance is superior to most traditional modelling methods. Additional gain of these algorithms 135 is the various loss functions that can be applied. Using the softmax loss function, we explicitly 136 estimated the class conditional probabilities, which allow us to demonstrate the performance of each of the classifiers both as "soft-classifiers" (i.e., predicting class probabilities) and "hard-137 138 classifiers" (i.e., setting a probability threshold and predicting a class). The former approximates 139 a continuous number as output - the class conditional probabilities - and then performs 140 classification based on these estimated probabilities. In contrast, hard classifiers output a discrete 141 number as the decision - directly targeting the classification decision boundary, without producing 142 the probability estimation.

- 143 A gradient boosting classifier was developed with a feature set of 132 miRNA predictors.
- 144 Dataset was partitioned to training-set (75%) and validation-set (25%) which was used as held-
- 145 out data. The training-set was cross-validated during training with stratified 3-fold cross
- validation. An ROC was generated for each of the folds and individual and mean AUCs were
- 147 calculated along with 95% confidence intervals.
- 148 The chosen hyper-parameters: ccp_alpha=0.0, learning_rate=0.5, max_depth=8,
- 149 max_features=0.45, min_samples_leaf=14, min_samples_split=8, n_estimators=100,
- 150 subsample=0.45 and tol=0.0001.

151 miRNA Predictor Selection by Recursive Feature Elimination (RFE)

152 For selecting the most predictive features during prediction model development, we used 153 Recursive Feature Elimination (RFE) algorithm, an efficient recursive approach for eliminating 154 features from a training dataset with 3-fold cross validation. ExtraTreesClassifier algorithm is used 155 cross-validated RFE procedure, with hyper-parameters: criterion="entropy", in the 156 max features=0.9, and n estimators=20. RFE works by iteratively removing features and using 157 model accuracy to identify which features contribute the most to prediction. Tree-based 158 importance scores of 132 miRNAs were used in order to rank features, and thus reduced the 159 dimension of miRNA measurements needed for prediction by ~90% (13 miRNA features in a 160 model in total). Additionally, the final model included age and sex as predictors (resulting in a of 161 total 15 predictors).

162 Feature Importance and SHAP Analysis

Although gradient boosting tree models are complex models, they can automatically provide an approximation of feature importance from the trained boosted trees. A miRNA predictor is assigned with an importance score in every single tree, where the Gini purity index is used to assess split points in the tree. The score of a feature is calculated based on the amount of improvement in the Gini index achieved by split points that include the feature, weighted by the number of observations in that node. The final importance score of a feature is calculated by an average across all decision trees within the final model.

170

For local interpretability of the predictive model, we used SHapley Additive exPlanations (SHAP) ⁷², the current state of the art in Machine Learning explainability tools. SHAP provides estimates and visualizations to infer what decisions the model is making. This is achieved by quantifying the contribution that each feature brings to each prediction made by the model.

175 Linear regression model

176 A linear classifier (Logistic Regression) was developed with a feature set of 95 miRNA predictors, 177 that were differentially expressed (adjusted p-value ≤ 0.05) between FTD cases and controls. 178 Each miRNA was binarized by its mean value. Training and validation were identical as in the 179 gradient boosting classifier: Dataset was partitioned to training-set (75%) and validation-set (25%) 180 which was used as held-out data. The training-set was cross-validated during training with 181 stratified 3-fold cross validation. An ROC was generated for each of the folds and individual and 182 mean AUCs were calculated along with 95% confidence intervals. The chosen hyperparams for 183 Logistic Regression: L2 penalty, tol=1e-4, fit intercept=True, solver='lbfgs', max iter=500.

184 **Results**

185 We sought to determine the overall diagnostic capability of miRNA measurements in FTD. To this 186 end, we based our study on analysis of plasma miRNA expression and the development of 187 computational diagnostic models. The cohort included a total of 293 participants, enrolled 188 between 2009 and 2018. Summary of participants' basic characteristics is shown in Table 1. Since 189 the non-neurodegenerative controls were collected in two centers, we first verified that they could 190 have been sampled from a single population and can therefore be considered a single cohort. We 191 estimated the Kullback-Leibler divergence, a measure of the difference between two probability 192 distributions. This analysis indicated only a small difference between the two sets in question (KL 193 = 0.293, Figure S1), that is further visualized by t-distributed stochastic neighbor embedding (t-194 SNE) analysis of the cohorts.

195 Differential expression of miRNAs

196 Out of the >2000 miRNA species that were aligned to the human genome, only 132 fulfilled QC 197 criteria of an average UMI count ≥ 100 across all samples and non-zero counts in all samples 198 (see Methods). Next, we quantified the differential miRNAs that may distinguish FTD from 199 controls. Ninety-five miRNAs were differentially expressed between plasma of patients with FTD 200 and controls, with an adjusted p-value<0.05 (Figure 1A). Additional analysis of only subsets of 201 C9ORF72-FTD cases (Figure 1B), FTD females (Figure 1C) or FTD males (Figure 1D) vs. 202 relevant controls revealed that the miRNA signature was comparable between the full FTD cohort 203 and subcategories (Table S2: Source Data Fig. 1). This was also true for subsets of FTD patients 204 with predicted TDP or Tau pathology (Figure S2).

205 Development of machine learning classifier for the diagnosis of FTD

We established a diagnostic prediction model for FTD on a randomly selected training set of 135
FTD cases and 84 controls, comprising 75% of the total cohort (168 cases, 125 controls). For
model validation, the remaining 25% of the data were held out as a replication cohort (33 FTD,
41 control samples).

The 132 miRNAs were tested as potential predictors, using an ensemble machine learning approach for ranking miRNAs predictive value in the diagnosis of FTD vs. individuals that did not suffer from neurodegeneration and were considered healthy. For selecting the most predictive features during model development, we used Recursive Feature Elimination (RFE), an efficient multivariate approach that iteratively removes miRNAs (features) and identifies those that

contribute the most to prediction accuracy. Cross validated RFE on the training set with Extra
 Tree classifiers, obtained a set of 13 miRNAs with highest feature importance (Figure 2A). Age
 and sex were added as predictors in the model, in addition to the selected 13 miRNAs features.

218 The prediction model presented a mean receiver operating characteristic area under the curve 219 (ROC AUC) of 0.94 under internal cross validation on training dataset (Figure 2B). Furthermore, 220 the 13-miRNA-based predictor was capable of predicting the diagnosis of FTD in an independent 221 held-out (replication) cohort of 74 individuals with an ROC AUC of 0.88 (Figure 2C). Additional 222 analysis reveals that the model is well calibrated and satisfactorily performs on held-out data 223 (Figure 2D). At a defined probability threshold (0.6), the classifier exhibits a 0.81 precision (PPV) 224 over 0.92 negative predictive value (NPV) with a 0.91 recall (sensitivity), a 0.83 specificity and a 225 0.08 false omission rate over 0.19 false discovery rate values (Figure 2E). Furthermore, a family 226 of models trained with only a subset of the 15 most predictive features, displays a stable AUC 227 ROC performance and reassures that the selected final features are suitable (Figure 2F). In 228 summary, we determined 13 miRNAs that are able to call the diagnosis of FTD with high accuracy. 229 We have further compared the non-linear machine-learning strategy (with 13 miRNA features 230 selected by multivariate RFE, Figure 2) to a logistic regression model with univariate feature 231 selction (Figure S3). A subset of 95 miRNAs out of the 132 passing QC, were differentially 232 expressed between FTD and controls (passing a threshold of p<0.05 after correction for multiple 233 hypotheses) and therefore were used in the logostic regression as features. Similarly, age and 234 sex were also included as predictors. The linear model with 95 differentially-expressed miRNAs, 235 age and sex was inferior to the gradient boosting classifier model, particularly by sensitivity (0.73) 236 vs 0.91) and negative predictive value (0.8 vs 0.92) (Figure S3). Moreover, the non-linear 237 approach showed better robustness in the different training folds and also outperforms the linear 238 model in utilizing a significantly smaller number of miRNA features (15 vs. 97), to obtain its 239 accuracy.

240 We then sought to better understand the machine-learning-based non-linear prediction model by 241 investigating the relative effect of each individual miRNA. Therefore, we utilized post-hoc SHapley 242 Additive exPlanations (SHAP) feature importance analysis to uncover the contribution of 243 individual miRNAs to the FTD diagnostic predictor (Figure 3A, B). Extreme SHAP values inform 244 that the model predicts a more likely FTD (positive values) or healthy control (negative values). 245 The key predictors revealed by SHAP, which contribute the most to calling FTD vs controls, are multiple sclerosis-associated miR-629^{73,74}, brain enriched miR-125b⁷⁵ and the astrocyte-derived 246 exosomal miR-361⁷⁶. We further tested each individual miRNA as a single predictor of FTD 247

9

248 diagnosis. A model with only miR-423-5p or miR-125b-5p presented the highest AUC values of 249 ~ 0.69 (Table 2). Boxplots depicting the underlying distribution of each of the 13 miRNA predictors, 250 along with scatter plots of the expression values of individual subjects in these miRNAs, confirm 251 the non-linear relationship between miRNA expression and the phenotype, for some miRNAs 252 (e.g., miR-107 and miR-26a), while other miRNAs can be divided to low/high values predominated 253 by either controls or FTD cases (e.g., miR-629-5p, Figure 4). These observations emphasize the 254 power of a model, which is able to take into account non-linear relationship between features 255 (miRNAs).

- Significant pairwise differences were noted in miR-107 levels in both bvFTD and SD vs other FTD subtypes (primary progressive aphasia, corticobasal syndrome, progressive supranuclear palsy and FTD with motor neuron disease. ANOVA: p=0.009, bvFTD vs other FTD subtypes: p=0.01, SD vs other FTD subtypes: p=0.02, Figure S4C). In addition, significant pairwise differences in miR-26a levels were found in both bvFTD (p=0.04) and PNFA (p=0.02) vs other FTD subtypes (ANOVA: p=0.024, bvFTD vs other FTD subtypes: p=0.04, PNFA vs other FTD subtypes: p=0.02, Figure S4F).
- None of the other miRNAs showed differences between clinical subtypes (Figure S4), between different mutation carriers, or between mutations carriers and patients with no known FTD mutations (Figure S5). In conclusion, a non-linear signature based on only 13 miRNAs is able to call the diagnosis of FTD with high accuracy and generalizability, for all FTD subtypes and independent of the underlying genetic background.
- 268 Finally, we tested the performance of plasma miRNA classifiers that were reported in previous 269 works ^{56,58}, relative to the classifier we have reported here. We replicated the logistic regression model (with L2 regularization^{77,78}) from the study of Kmetzsch et al. ⁵⁸ on our data. Taking miR-270 271 34a-5p, miR-345-5p, miR-200c-3p and miR-10a-3p as features, displayed inferiority to our model. 272 Moreover, these miRNAs were not differentially expressed between cases and controls in our 273 study. Next, we replicated the "microRNA pair" approach from the study of Sheinerman et al. ⁵⁶: 274 miR-335/let-7e, miR-99b/let-7e and miR-9-3p/miR-181a and assessed the ROC curves, showing 275 they are inferior to our non-linear classifier in distinguishing between FTD and controls (Figure 5). 276 Thus, when tested in comparison to reported miRNA classifiers from the literature, our panels of 277 miRNA and non-linear classifier perform better, with AUC values of 0.9.

10

278 Discussion

279 The need to facilitate the diagnosis of FTD in the face of clinical heterogeneity raises the hope for 280 new effective biomarkers. Circulating miRNAs hold a fascinating potential as diagnostic biomarkers that were not fully explored, including for brain disorders ⁵⁰. We recently demonstrated 281 282 the power of miRNAs in prognosis and prediction of clinical response to therapy in motor neuron 283 diseases ^{51,52}. In the present work, we sought to discover diagnostic biomarkers for FTD. By using 284 an unbiased, next generation sequencing approach and advanced computation in a discovery 285 cohort of 219 subjects and 74 additional subjects for a replication study, we overcame limitations 286 of past works in developing biomarkers for FTD. A recursive non-linear approach was utilized to 287 find the smallest set of miRNA features that obtain the highest accuracy of the prediction model, 288 leading to a signature of 13 miRNAs only. Thus, our miRNA-based binary classifier is more 289 accurate and robust than published miRNA-based predictors ^{56,58}.

The use of gradient boosting trees, an ensemble learning approach, allows discovering nonlinear relationships between miRNAs and disease status that gained affirmation by cross validation in the training dataset. Furthermore, our model is externally validated on held-out data, which was not used during feature selection and model development, according to the TRIPOD guidelines ⁶³. SHAP analysis ⁷² further unfolds the relative contribution of individual features to the predictive model. Of note, the performance of the ensemble learning was superior to that of a logistic regression model, and enabled the use of only 15 features, instead of 97, for prediction.

297 According to the human miRNA tissue atlas ⁷⁵, most of the selected miRNAs are CNS-enriched 298 (let-7c-5p, miR-26a-5p, miR-107, miR-125b-5p), suggesting that they might be directly involved 299 in the disease state of the CNS. miR-26a, miR-326, miR-484 and miR-361 were associated with 300 FTD diagnosis in our data and with cognitive deficits or Alzheimer's disease (AD) in other analyses ⁷⁹⁻⁸⁵. In mice, miR-326 inhibited Tau phosphorylation⁸⁰, a hallmark of FTD as well as AD, 301 302 supranuclear palsy (PSP), conticobasal syndrome (CBD) and chronic traumatic encephalopathy 303 (CTE)⁸⁶. Brain-enriched miR-107 was also implicated in AD ⁸⁷⁻⁹². Changes in blood levels of miR-304 326, miR-26a, and miR-629 are associated with multiple sclerosis (MS), a condition characterized by demyelination ⁹³⁻¹⁰⁰. Moreover, serum miR-629 was negatively correlated with MS patient brain 305 306 volume and lesion severity, respectively ¹⁰¹. Thus, some of the miRNA predictors proposed here 307 are associated directly or indirectly with other degenerative brain diseases.

308 Conclusion

309 Strengths and Limitations

310 We have found specific molecular miRNA patterns that can contribute to the diagnosis of FTD. 311 Therefore, the work encourages testing if circulating miRNAs biomarkers can establish a cost-312 effective screening approach to increase speed or precision in the diagnosis of suspected FTD. 313 Early-stage diagnosis may be useful towards design of prospective clinical trials. More broadly, 314 the findings demonstrate the importance of integrating machine learning into clinical biomarker 315 studies, addressing nonlinearity and exposing otherwise cryptic disease-associated signals. 316 Finally, while ongoing biomarker studies in FTD highlight protein markers such as NfL and Tau, 317 combined protein-RNA markers may present increased accuracy, as we previously showed⁵². 318 We would like to put forward a few notable limitations of our study: First, patients in our cohorts 319 were most likely recruited in different phases of the disease, which results in significant phenotypic 320 heterogeneity. At the same time, since we had no record of disease severity, we could not stratify 321 patients by their disease phase and depict stage-dependent changes in miRNAs. Additionally, we 322 did not find any miRNAs, which can differentiate between FTD-Tau and FTD-TDP, which might 323 result from small, underpowered subset cohorts or could highlight a wider role for these novel 324 biomarkers within dementia syndromes. We hope that in the future, larger cohorts can be used to 325 reveal such differences. Finally, a long route is expected from this initial study and until miRNA 326 can be used in personalized diagnosis. These steps shall include prospective studies, quantitative 327 calibration of absolute miRNA concentrations and simple bed-side methods for quantification of

328 miRNAs.

329 Unanswered questions

330 It remains to be determined why our findings are discrepant with conclusions of past studies ⁵³⁻ 331 ^{60,62}. For studies in other bodily fluids the answer might be trivially-related to the different biofluid composition^{53,57,60}. Furthermore, we emphasize the progress we presented in our study in terms 332 333 of power (larger cohort) and the unbiased analysis by next generation microRNA sequencing, that 334 contrasts past biased choices of miRNA candidates. A second unanswered question is why 335 defined nonlinear patterns are strongly predictive of disease states. Future works should address 336 the differential diagnosis between FTD and other dementias, such as Alzheimer's disease. Lastly, 337 protein based markers, such as neurofilaments, lack specificity to particular neurodegenerative 338 diseases. However, it is plausible that miRNAs might demonstrate a disease-specific pattern in 339 the circulation. Future studies with large AD and FTD cohorts might address this hypothesis.

340 **Recommendations**

In our study we took care to keep a held-out cohort for external validation. To substantiate our work and towards clinical diagnostic usage, it is warranted to validate the predictor by testing it on an independent cohort of different ethnicity and create means for quantification of absolute miRNA concentrations. In addition, miRNA levels should be compared in follow up works, and combined with other experimental circulating markers of neurodegeneration such as neurofilaments. In addition, miRNAs could be explored also as prognostic markers in FTD and in predicting disease severity.

348 Availability of supporting data

The data that support the findings of this study are available from the corresponding author upon reasonable request.

351 Appendix

352 IDs of 34 subjects removed due to age-based QC:

353 'CTRL_rep9', 'CTRL_rep10', 'CTRL_rep13', 'CTRL_rep19', 'CTRL_rep16', 'CTRL_rep18',
354 'CTRL_rep20', 'FTD30', 'CTRL_rep17', 'CTRL12', 'CTRL13', 'CTRL2', 'CTRL5', 'CTRL56',
355 'CTRL57', 'CTRL58', 'CTRL68', 'CTRL100', 'CTRL111', 'CTRL20', 'CTRL22', 'CTRL23', 'CTRL24',
356 'CTRL27', 'CTRL29', 'CTRL33', 'CTRL48', 'CTRL50', 'CTRL54', 'CTRL60','CTRL62', 'CTRL73',
357 'CTRL82', 'CTRL83'.

358 Acknowledgements

We thank Vittoria Lombardi (UCL) for technical assistance. We acknowledge patients with FTD, and healthy volunteers for their contribution and ALS biomarkers study co-workers for biobanking, which has made this study possible (REC 09/H0703/27). We also thank the North Thames Local Research Network (LCRN) for its support. EH is the Mondry Family Professorial Chair and Head of the Nella and Leon Benoziyo Center for Neurological Diseases and of the Andi and Larry Wolfe Center for Neuroimmunology and Neuromodulation.

365 Funding

Research at the Hornstein laboratory is supported by the CReATe consortium and ALSA
(program: "Prognostic Value of miRNAs in Biofluids From ALS Patients"), the RADALA
Foundation; AFM Telethon (20576); the Weizmann Center for Research on Neurodegeneration

369 at Weizmann Institute of Science; the Minerva Foundation, with funding from the Federal German 370 Ministry for Education and Research; the ISF Legacy Heritage Fund (828/17); the Israel Science 371 Foundation (135/16, 3497/21, 424/22, 425/22); United States - Israel Binational Science 372 Foundation (#2021181); A research grant from the Anita James Rosen Foundation; Target ALS 373 (118945); the Thierry Latran Foundation for ALS Research; the European Research Council 374 under the European Union's Seventh Framework Program ([FP7/2007-2013]/ERC grant 375 agreement number 617351); ERA-Net for Research Programs on Rare Diseases (eRARE FP7) 376 via the Israel Ministry of Health; Dr Sydney Brenner and friends; Edward and Janie Moravitz; A. 377 Alfred Taubman through IsrALS; Yeda-Sela; Yeda-CEO; the Israel Ministry of Trade and Industry; 378 the Y. Leon Benoziyo Institute for Molecular Medicine; the Nella and Leon Benoziyo Center for 379 Neurological Disease; the Kekst Family Institute for Medical Genetics; the David and Fela Shapell 380 Family Center for Genetic Disorders Research; the Crown Human Genome Center; the Nathan, 381 Shirley, Philip, and Charlene Vener New Scientist Fund; the Julius and Ray Charlestein 382 Foundation; the Fraida Foundation; the Wolfson Family Charitable Trust; the Adelis Foundation; 383 Merck (UK); M. Halphen; the estates of F. Sherr, L. Asseof, and L. Fulop; the Goldhirsh-Yellin 384 Foundation; the Redhill Foundation-Sam and Jean Rothberg Charitable Trust; Dr. Dvora and 385 Haim Teitelbaum Endowment Fund: A research grant from the Anita James Rosen Foundation. 386 The ALS-Therapy Alliance, Motor Neuron Disease Association (UK); this work was supported by 387 the Motor Neuron Disease Association (MNDA) 839-791.

388 The Dementia Research Centre is supported by Alzheimer's Research UK, Brain Research Trust, 389 and The Wolfson Foundation. This work was supported by the NIHR Queen Square Dementia 390 Biomedical Research Unit, the NIHR UCL/H Biomedical Research Centre and the Leonard 391 Wolfson Experimental Neurology Centre (LWENC) Clinical Research Facility as well as an 392 Alzheimer's Society grant (AS-PG-16-007). JDR is supported by an MRC Clinician Scientist 393 Fellowship (MR/M008525/1) and has received funding from the NIHR Rare Disease Translational 394 Research Collaboration (BRC149/NS/MH). PF is supported by a Medical Research Council 395 Senior Clinical Fellowship, an MRC/MND LEW Fellowship, the NIHR UCLH BRC and the Lady 396 Edith Wolfson Fellowship scheme (MR/M008606/1 and MR/S006508/1).

NSY was supported by the Israeli Council for Higher Education (CHE) via the Weizmann Data
Science Research Center, by a research grant from the Estate of Tully and Michele Plesser and
by Maccabim Foundation. I.M. was supported by Teva Pharmaceutical Industries as part of the
Israeli National Network of Excellence in Neuroscience (fellowship no. 117941).

- 401
- 402

403 Authors' contribution

- 404 I.M., P.F., J.D.R. and E.H. conceived research.
- 405 I.M., N.S.Y. and E.H. analyzed the data.
- 406 A.M. and J.D.R. established cohort, gained ethical approval and collected human samples for
- 407 research.
- 408 Y.B., C.H. and I.S. assisted research.
- 409 I.M., N.S.Y., P.F., A.M., J.D.R. and E.H. wrote the manuscript, with comments and final
- 410 approval by all other authors.
- 411 J.D.W. provided resources for research and input in research development.
- 412 A.M. and J.D.R. are corresponding authors for cohorts and clinical data. P.F. and E.H. are
- 413 corresponding authors for all other facets of the work.
- 414 All authors read and approved the final manuscript.

415 **Declarations of interest**

416 None.

417 **References**

McKhann GM, Albert MS, Grossman M, et al. Clinical and pathological diagnosis of
frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick's
Disease. *Arch Neurol.* Nov 2001;58(11):1803-9. doi:10.1001/archneur.58.11.1803

Seelaar H, Rohrer JD, Pijnenburg YA, Fox NC, van Swieten JC. Clinical, genetic and
pathological heterogeneity of frontotemporal dementia: a review. *J Neurol Neurosurg Psychiatry*.
May 2011;82(5):476-86. doi:10.1136/jnnp.2010.212225

424 3. Convery R, Mead S, Rohrer JD. Review: Clinical, genetic and neuroimaging features of 425 frontotemporal dementia. *Neuropathol Appl Neurobiol*. Feb 2019;45(1):6-18. 426 doi:10.1111/nan.12535

427 4. Deleon J, Miller BL. Frontotemporal dementia. *Handb Clin Neurol*. 2018;148:409-430. 428 doi:10.1016/B978-0-444-64076-5.00027-2

429 5. DeJesus-Hernandez M, Mackenzie IR, Boeve BF, et al. Expanded GGGGCC 430 hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and 431 ALS. *Neuron*. Oct 20 2011;72(2):245-56. doi:10.1016/j.neuron.2011.09.011

432 6. Renton AE, Majounie E, Waite A, et al. A hexanucleotide repeat expansion in C9ORF72
433 is the cause of chromosome 9p21-linked ALS-FTD. *Neuron*. Oct 20 2011;72(2):257-68.
434 doi:10.1016/j.neuron.2011.09.010

- 435 7. Hutton M, Lendon CL, Rizzu P, et al. Association of missense and 5'-splice-site mutations
 436 in tau with the inherited dementia FTDP-17. *Nature*. Jun 18 1998;393(6686):702-5.
 437 doi:10.1038/31508
- 8. Skibinski G, Parkinson NJ, Brown JM, et al. Mutations in the endosomal ESCRTIIIcomplex subunit CHMP2B in frontotemporal dementia. *Nat Genet*. Aug 2005;37(8):806-8.
 doi:10.1038/ng1609

441 9. Baker M, Mackenzie IR, Pickering-Brown SM, et al. Mutations in progranulin cause tau-442 negative frontotemporal dementia linked to chromosome 17. *Nature*. Aug 24 443 2006;442(7105):916-9. doi:10.1038/nature05016

- 444 10. Borroni B, Bonvicini C, Alberici A, et al. Mutation within TARDBP leads to frontotemporal
 445 dementia without motor neuron disease. *Hum Mutat.* Nov 2009;30(11):E974-83.
 446 doi:10.1002/humu.21100
- 447 11. Pottier C, Bieniek KF, Finch N, et al. Whole-genome sequencing reveals important role
 448 for TBK1 and OPTN mutations in frontotemporal lobar degeneration without motor neuron
 449 disease. *Acta Neuropathol.* Jul 2015;130(1):77-92. doi:10.1007/s00401-015-1436-x
- 450 12. Watts GD, Wymer J, Kovach MJ, et al. Inclusion body myopathy associated with Paget
 451 disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein. *Nat* 452 *Genet*. Apr 2004;36(4):377-81. doi:10.1038/ng1332
- 453 13. Lippa CF, Zhukareva V, Kawarai T, et al. Frontotemporal dementia with novel tau 454 pathology and a Glu342Val tau mutation. *Ann Neurol*. Dec 2000;48(6):850-8.
- 455 14. Neumann M, Sampathu DM, Kwong LK, et al. Ubiquitinated TDP-43 in frontotemporal
 456 lobar degeneration and amyotrophic lateral sclerosis. *Science*. Oct 6 2006;314(5796):130-3.
 457 doi:10.1126/science.1134108
- 458 15. Snowden JS, Neary D, Mann DM. Frontotemporal dementia. *Br J Psychiatry*. Feb 459 2002;180:140-3.
- 460 16. Olney NT, Spina S, Miller BL. Frontotemporal Dementia. *Neurol Clin*. May 2017;35(2):339-461 374. doi:10.1016/j.ncl.2017.01.008
- 462 17. Strong MJ, Abrahams S, Goldstein LH, et al. Amyotrophic lateral sclerosis frontotemporal
 463 spectrum disorder (ALS-FTSD): Revised diagnostic criteria. *Amyotroph Lateral Scler*464 *Frontotemporal Degener*. May 2017;18(3-4):153-174. doi:10.1080/21678421.2016.1267768

465 18. Teunissen CE, Elias N, Koel-Simmelink MJ, et al. Novel diagnostic cerebrospinal fluid
466 biomarkers for pathologic subtypes of frontotemporal dementia identified by proteomics.
467 *Alzheimers Dement (Amst)*. 2016;2:86-94. doi:10.1016/j.dadm.2015.12.004

468 19. Sheikh-Bahaei N, Sajjadi SA, Pierce AL. Current role for biomarkers in clinical diagnosis
469 of Alzheimer disease and frontotemporal dementia. *Current treatment options in neurology*.
470 2017;19(12):46.

471 20. Neeter LH, Kaat LD, Rohrer JD, Van Swieten JC. Imaging and fluid biomarkers in 472 frontotemporal dementia. *Nature Reviews Neurology*. 2017;13(7):406.

473 21. Meeter LHH, Vijverberg EG, Del Campo M, et al. Clinical value of neurofilament and 474 phospho-tau/tau ratio in the frontotemporal dementia spectrum. *Neurology*. Apr 3 475 2018;90(14):e1231-e1239. doi:10.1212/WNL.000000000005261

476 22. Feneberg E, Gray E, Ansorge O, Talbot K, Turner MR. Towards a TDP-43-Based 477 Biomarker for ALS and FTLD. *Mol Neurobiol*. Oct 2018;55(10):7789-7801. doi:10.1007/s12035-478 018-0947-6

479 23. Forgrave LM, Ma M, Best JR, DeMarco ML. The diagnostic performance of neurofilament
480 light chain in CSF and blood for Alzheimer's disease, frontotemporal dementia, and amyotrophic
481 lateral sclerosis: A systematic review and meta-analysis. *Alzheimers Dement (Amst)*. Dec
482 2019;11:730-743. doi:10.1016/j.dadm.2019.08.009

483 24. Delaby C, Alcolea D, Carmona-Iragui M, et al. Differential levels of Neurofilament Light
484 protein in cerebrospinal fluid in patients with a wide range of neurodegenerative disorders. *Sci*485 *Rep.* Jun 8 2020;10(1):9161. doi:10.1038/s41598-020-66090-x

486 25. van der Ende EL, Xiao M, Xu D, et al. Neuronal pentraxin 2: a synapse-derived CSF 487 biomarker in genetic frontotemporal dementia. *J Neurol Neurosurg Psychiatry*. Jun 488 2020;91(6):612-621. doi:10.1136/jnnp-2019-322493

Ashton NJ, Janelidze S, Al Khleifat A, et al. A multicentre validation study of the diagnostic
value of plasma neurofilament light. *Nat Commun.* Jun 7 2021;12(1):3400. doi:10.1038/s41467021-23620-z

492 27. Katisko K, Cajanus A, Huber N, et al. GFAP as a biomarker in frontotemporal dementia
493 and primary psychiatric disorders: diagnostic and prognostic performance. *J Neurol Neurosurg*494 *Psychiatry*. Dec 2021;92(12):1305-1312. doi:10.1136/jnnp-2021-326487

495 28. Verde F, Otto M, Silani V. Neurofilament Light Chain as Biomarker for Amyotrophic Lateral
496 Sclerosis and Frontotemporal Dementia. *Front Neurosci.* 2021;15:679199.
497 doi:10.3389/fnins.2021.679199

498 29. Wilson KM, Katona E, Glaria I, et al. Development of a sensitive trial-ready poly(GP) CSF 499 biomarker assay for C9orf72-associated frontotemporal dementia and amyotrophic lateral 500 sclerosis. *J Neurol Neurosurg Psychiatry*. Jul 2022;93(7):761-771. doi:10.1136/jnnp-2021-501 328710

502 30. Katisko K, Cajanus A, Jaaskelainen O, et al. Serum neurofilament light chain is a 503 discriminative biomarker between frontotemporal lobar degeneration and primary psychiatric 504 disorders. *J Neurol*. Jan 2020;267(1):162-167. doi:10.1007/s00415-019-09567-8

505 31. Hansson O, Santillo AF, Meeter LH, et al. CSF placental growth factor - a novel candidate 506 biomarker of frontotemporal dementia. *Ann Clin Transl Neurol*. May 2019;6(5):863-872. 507 doi:10.1002/acn3.763

508 32. Al Shweiki MR, Steinacker P, Oeckl P, et al. Neurofilament light chain as a blood 509 biomarker to differentiate psychiatric disorders from behavioural variant frontotemporal dementia. 510 *J Psychiatr Res.* Jun 2019;113:137-140. doi:10.1016/j.jpsychires.2019.03.019

511 33. Borroni B, Benussi A, Archetti S, et al. Csf p-tau181/tau ratio as biomarker for TDP 512 pathology in frontotemporal dementia. *Amyotroph Lateral Scler Frontotemporal Degener*. Mar 513 2015;16(1-2):86-91. doi:10.3109/21678421.2014.971812

514 34. Bourbouli M, Rentzos M, Bougea A, et al. Cerebrospinal Fluid TAR DNA-Binding Protein 515 43 Combined with Tau Proteins as a Candidate Biomarker for Amyotrophic Lateral Sclerosis and

516 Frontotemporal Dementia Spectrum Disorders. *Dement Geriatr Cogn Disord*. 2017;44(3-4):144-517 152. doi:10.1159/000478979

 518
 35.
 Hu WT, Watts K, Grossman M, et al. Reduced CSF p-Tau181 to Tau ratio is a biomarker

 519
 for
 FTLD-TDP.
 Neurology.
 Nov
 26
 2013;81(22):1945-52.

 520
 doi:10.1212/01.wnl.0000436625.63650.27
 Nov
 26
 2013;81(22):1945-52.

521 36. Jiskoot LC, Panman JL, Meeter LH, et al. Longitudinal multimodal MRI as prognostic and 522 diagnostic biomarker in presymptomatic familial frontotemporal dementia. *Brain*. Jan 1 523 2019;142(1):193-208. doi:10.1093/brain/awy288

524 37. McCarthy J, Collins DL, Ducharme S. Morphometric MRI as a diagnostic biomarker of 525 frontotemporal dementia: A systematic review to determine clinical applicability. *Neuroimage Clin*. 526 2018;20:685-696. doi:10.1016/j.nicl.2018.08.028

527 38. Niikado M, Chrem-Mendez P, Itzcovich T, et al. Evaluation of Cerebrospinal Fluid 528 Neurofilament Light Chain as a Routine Biomarker in a Memory Clinic. *J Gerontol A Biol Sci Med* 529 *Sci*. Mar 14 2019;74(4):442-445. doi:10.1093/gerona/gly179

530 39. Benussi A, Karikari TK, Ashton N, et al. Diagnostic and prognostic value of serum NfL and 531 p-Tau(181) in frontotemporal lobar degeneration. *J Neurol Neurosurg Psychiatry*. Sep 532 2020;91(9):960-967. doi:10.1136/jnnp-2020-323487

40. Das S, Dewit N, Jacobs D, et al. A Novel Neurofilament Light Chain ELISA Validated in Patients with Alzheimer's Disease, Frontotemporal Dementia, and Subjective Cognitive Decline, and the Evaluation of Candidate Proteins for Immunoassay Calibration. *Int J Mol Sci.* Jun 29 2022;23(13)doi:10.3390/ijms23137221

537 41. Bellini S, Saraceno C, Benussi L, et al. Plasma Small Extracellular Vesicles with 538 Complement Alterations in GRN/C9orf72 and Sporadic Frontotemporal Lobar Degeneration. 539 *Cells*. Jan 30 2022;11(3)doi:10.3390/cells11030488

540 42. Chouliaras L, Thomas A, Malpetti M, et al. Differential levels of plasma biomarkers of
541 neurodegeneration in Lewy body dementia, Alzheimer's disease, frontotemporal dementia and
542 progressive supranuclear palsy. *J Neurol Neurosurg Psychiatry*. Jun 2022;93(6):651-658.
543 doi:10.1136/jnnp-2021-327788

544 43. Eratne D, Loi SM, Li QX, et al. Cerebrospinal fluid neurofilament light chain differentiates
545 primary psychiatric disorders from rapidly progressive, Alzheimer's disease and frontotemporal
546 disorders in clinical settings. *Alzheimers Dement*. Feb 1 2022;doi:10.1002/alz.12549

547 44. Krishnan G, Raitcheva D, Bartlett D, et al. Poly(GR) and poly(GA) in cerebrospinal fluid 548 as potential biomarkers for C9ORF72-ALS/FTD. *Nat Commun*. May 19 2022;13(1):2799. 549 doi:10.1038/s41467-022-30387-4

45. Oeckl P, Anderl-Straub S, Von Arnim CAF, et al. Serum GFAP differentiates Alzheimer's
 disease from frontotemporal dementia and predicts MCI-to-dementia conversion. *J Neurol Neurosurg Psychiatry*. Apr 27 2022;doi:10.1136/jnnp-2021-328547

553 46. Silva-Spinola A, Lima M, Leitao MJ, et al. Serum neurofilament light chain as a surrogate 554 of cognitive decline in sporadic and familial frontotemporal dementia. *Eur J Neurol.* Jan 555 2022;29(1):36-46. doi:10.1111/ene.15058

556 47. Thijssen EH, Verberk IMW, Kindermans J, et al. Differential diagnostic performance of a 557 panel of plasma biomarkers for different types of dementia. *Alzheimers Dement (Amst)*. 558 2022;14(1):e12285. doi:10.1002/dad2.12285

55948.Meeter LH, Dopper EG, Jiskoot LC, et al. Neurofilament light chain: a biomarker for genetic560frontotemporal dementia. Ann Clin Transl Neurol. Aug 2016;3(8):623-36. doi:10.1002/acn3.325

561 49. Coenen-Stass AML, Magen I, Brooks T, et al. Evaluation of methodologies for microRNA 562 biomarker detection by next generation sequencing. *RNA Biol.* 2018;15(8):1133-1145. 563 doi:10.1080/15476286.2018.1514236

564 50. van den Berg MMJ, Krauskopf J, Ramaekers JG, Kleinjans JCS, Prickaerts J, Briede JJ. 565 Circulating microRNAs as potential biomarkers for psychiatric and neurodegenerative disorders. 566 *Prog Neurobiol.* Feb 2020;185:101732. doi:10.1016/j.pneurobio.2019.101732

567 51. Magen I, Aharoni S, Yacovzada NS, et al. Muscle microRNAs in the cerebrospinal fluid 568 predict clinical response to nusinersen therapy in type II and type III spinal muscular atrophy 569 patients. *Eur J Neurol.* Aug 2022;29(8):2420-2430. doi:10.1111/ene.15382

570 52. Magen I, Yacovzada NS, Yanowski E, et al. Circulating miR-181 is a prognostic biomarker 571 for amyotrophic lateral sclerosis. *Nat Neurosci*. Nov 2021;24(11):1534-1541. 572 doi:10.1038/s41593-021-00936-z

573 Denk J, Oberhauser F, Kornhuber J, et al. Specific serum and CSF microRNA profiles 53. 574 distinguish sporadic behavioural variant of frontotemporal dementia compared with Alzheimer 575 patients and cognitively healthy controls. PLoS One. 2018;13(5):e0197329. 576 doi:10.1371/journal.pone.0197329

577 54. Grasso M, Piscopo P, Talarico G, et al. Plasma microRNA profiling distinguishes patients 578 with frontotemporal dementia from healthy subjects. *Neurobiol Aging*. Feb 5 579 2019;doi:10.1016/j.neurobiolaging.2019.01.024

580 55. Piscopo P, Grasso M, Puopolo M, et al. Circulating miR-127-3p as a Potential Biomarker 581 for Differential Diagnosis in Frontotemporal Dementia. *J Alzheimers Dis*. 2018;65(2):455-464. 582 doi:10.3233/JAD-180364

583 56. Sheinerman KS, Toledo JB, Tsivinsky VG, et al. Circulating brain-enriched microRNAs as 584 novel biomarkers for detection and differentiation of neurodegenerative diseases. *Alzheimers Res* 585 *Ther*. Nov 9 2017;9(1):89. doi:10.1186/s13195-017-0316-0

586 57. Schneider R, McKeever P, Kim T, et al. Downregulation of exosomal miR-204-5p and 587 miR-632 as a biomarker for FTD: a GENFI study. *J Neurol Neurosurg Psychiatry*. Aug 588 2018;89(8):851-858. doi:10.1136/jnnp-2017-317492

589 58. Kmetzsch V, Anquetil V, Saracino D, et al. Plasma microRNA signature in presymptomatic 590 and symptomatic subjects with C9orf72-associated frontotemporal dementia and amyotrophic 591 lateral sclerosis. *Journal of Neurology, Neurosurgery & Psychiatry*. 2021;92(5):485-493.

592 59. Sproviero D, Gagliardi S, Zucca S, et al. Different miRNA Profiles in Plasma Derived Small
593 and Large Extracellular Vesicles from Patients with Neurodegenerative Diseases. *Int J Mol Sci.*594 Mar 8 2021;22(5)doi:10.3390/ijms22052737

595 60. Tan YJ, Wong BYX, Vaidyanathan R, et al. Altered Cerebrospinal Fluid Exosomal 596 microRNA Levels in Young-Onset Alzheimer's Disease and Frontotemporal Dementia. *J* 597 *Alzheimers Dis Rep.* 2021;5(1):805-813. doi:10.3233/ADR-210311

598 61. Muller M, Kuiperij HB, Versleijen AA, et al. Validation of microRNAs in Cerebrospinal Fluid 599 as Biomarkers for Different Forms of Dementia in a Multicenter Study. *J Alzheimers Dis*. Apr 16 600 2016;52(4):1321-33. doi:10.3233/JAD-160038

601 62. Pounders J, Hill EJ, Hooper D, et al. MicroRNA expression within neuronal-derived small 602 extracellular vesicles in frontotemporal degeneration. *Medicine (Baltimore)*. Oct 7 603 2022;101(40):e30854. doi:10.1097/MD.000000000030854

604 63. Collins GS, Reitsma JB, Altman DG, Moons KG. Transparent Reporting of a multivariable 605 prediction model for Individual Prognosis or Diagnosis (TRIPOD): the TRIPOD statement. *Ann* 606 *Intern Med.* Jan 6 2015;162(1):55-63. doi:10.7326/M14-0697

607 64. Kohen R, Barlev J, Hornung G, et al. UTAP: User-friendly Transcriptome Analysis 608 Pipeline. *BMC bioinformatics*. 2019;24:154.

609 65. Kozomara A, Griffiths-Jones S. miRBase: annotating high confidence microRNAs using 610 deep sequencing data. *Nucleic Acids Res.* Jan 2014;42(Database issue):D68-73. 611 doi:10.1093/nar/gkt1181

612 66. Kho AT, Sharma S, Davis JS, et al. Circulating MicroRNAs: Association with Lung 613 Function in Asthma. *PLoS One*. 2016;11(6):e0157998. doi:10.1371/journal.pone.0157998

614 67. Wander PL, Enquobahrie DA, Bammler TK, et al. Associations of plasma miRNAs with

615 waist circumference and insulin resistance among women with polycystic ovary syndrome - Pilot

616 study. *Mol Cell Endocrinol*. Aug 20 2022;554:111723. doi:10.1016/j.mce.2022.111723

617 68. Wang A, Kwee LC, Grass E, et al. Whole blood sequencing reveals circulating microRNA
618 associations with high-risk traits in non-ST-segment elevation acute coronary syndrome.
619 *Atherosclerosis*. Jun 2017;261:19-25. doi:10.1016/j.atherosclerosis.2017.03.041

620 69. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for 621 RNA-seq data with DESeq2. *Genome Biol*. 2014;15(12):550. doi:10.1186/s13059-014-0550-8

622 70. Elith J, Leathwick JR, Hastie T. A working guide to boosted regression trees. *J Anim Ecol.* 623 Jul 2008;77(4):802-13. doi:10.1111/j.1365-2656.2008.01390.x

624 71. Witten IH, Frank E, Hall MA, Pal CJ. Ensemble Learning. In: Witten IH, Frank E, Hall MA, 625 Pal CJ, eds. *Data Mining (Fourth Edition)*. Morgan Kaufmann; 2017:479-501:chap 12.

626 72. Lundberg SM, Erion G, Chen H, et al. From local explanations to global understanding 627 with explainable AI for trees. *Nature Machine Intelligence*. 17 january 2020 2020;2:56-67.

62873.Liu F, Li T, Hu P, Dai L. Upregulation of Serum miR-629 Predicts Poor Prognosis for Non-629Small-Cell Lung Cancer. *Dis Markers*. 2021;2021:8819934. doi:10.1155/2021/8819934

630 74. Jingushi K, Ueda Y, Kitae K, et al. miR-629 Targets TRIM33 to Promote TGFbeta/Smad
631 Signaling and Metastatic Phenotypes in ccRCC. *Mol Cancer Res.* Mar 2015;13(3):565-74.
632 doi:10.1158/1541-7786.MCR-14-0300

633 75. Ludwig N, Leidinger P, Becker K, et al. Distribution of miRNA expression across human
634 tissues. *Nucleic Acids Research*. 2016;44(8):3865-3877. doi:10.1093/nar/gkw116

635 76. Bu X, Li D, Wang F, Sun Q, Zhang Z. Protective Role of Astrocyte-Derived Exosomal
636 microRNA-361 in Cerebral Ischemic-Reperfusion Injury by Regulating the AMPK/mTOR
637 Signaling Pathway and Targeting CTSB. *Neuropsychiatr Dis Treat*. 2020;16:1863-1877.
638 doi:10.2147/NDT.S260748

Froblems. *Technometrics*. 1970/02/01 1970;12(1):55-67. doi:10.1080/00401706.1970.10488634
Hoerl AE, Kennard RW. Ridge Regression: Applications to Nonorthogonal Problems. *Technometrics*. 1970/02/01 1970;12(1):69-82. doi:10.1080/00401706.1970.10488635

643 79. Chang WS, Wang YH, Zhu XT, Wu CJ. Genome-Wide Profiling of miRNA and mRNA
644 Expression in Alzheimer's Disease. *Med Sci Monit*. Jun 4 2017;23:2721-2731.
645 doi:10.12659/msm.905064

80. He B, Chen W, Zeng J, Tong W, Zheng P. MicroRNA-326 decreases tau phosphorylation
and neuron apoptosis through inhibition of the JNK signaling pathway by targeting VAV1 in
Alzheimer's disease. *J Cell Physiol*. Jan 2020;235(1):480-493. doi:10.1002/jcp.28988

81. Ludwig N, Fehlmann T, Kern F, et al. Machine Learning to Detect Alzheimer's Disease
from Circulating Non-coding RNAs. *Genomics Proteomics Bioinformatics*. Aug 2019;17(4):430440. doi:10.1016/j.gpb.2019.09.004

Allach El Khattabi L, Heide S, Caberg J-H, et al. 16p13.11 microduplication in 45 new
patients: refined clinical significance and genotype–phenotype correlations. *Journal of Medical Genetics*. 2020;57(5):301-307. doi:10.1136/jmedgenet-2018-105389

83. Goncalves TF, Piergiorge RM, Dos Santos JM, Gusmao J, Pimentel MMG, SantosReboucas CB. Network Profiling of Brain-Expressed X-Chromosomal MicroRNA Genes
Implicates Shared Key MicroRNAs in Intellectual Disability. *J Mol Neurosci*. Feb 2019;67(2):295304. doi:10.1007/s12031-018-1235-7

84. Wingo TS, Yang J, Fan W, et al. Brain microRNAs associated with late-life depressive
symptoms are also associated with cognitive trajectory and dementia. *NPJ Genom Med.*2020;5:6. doi:10.1038/s41525-019-0113-8

85. Cogswell JP, Ward J, Taylor IA, et al. Identification of miRNA changes in Alzheimer's
disease brain and CSF yields putative biomarkers and insights into disease pathways. J
Alzheimers Dis. May 2008;14(1):27-41. doi:10.3233/jad-2008-14103

665 Rawat P, Sehar U, Bisht J, Selman A, Culberson J, Reddy PH. Phosphorylated Tau in 86. 666 Disease Other Tauopathies. Int Alzheimer's and J Mol Sci. Oct 25 667 2022;23(21)doi:10.3390/ijms232112841

87. Muller M, Kuiperij HB, Claassen JA, Kusters B, Verbeek MM. MicroRNAs in Alzheimer's
disease: differential expression in hippocampus and cell-free cerebrospinal fluid. *Neurobiol Aging*.
Jan 2014;35(1):152-8. doi:10.1016/j.neurobiolaging.2013.07.005

671 88. Nelson PT, Wang WX. MiR-107 is reduced in Alzheimer's disease brain neocortex: 672 validation study. *J Alzheimers Dis*. 2010;21(1):75-9. doi:10.3233/JAD-2010-091603

673 89. Prendecki M, Florczak-Wyspianska J, Kowalska M, et al. APOE genetic variants and 674 apoE, miR-107 and miR-650 levels in Alzheimer's disease. *Folia Neuropathol.* 2019;57(2):106-675 116. doi:10.5114/fn.2019.84828

Wang J, Chen C, Zhang Y. An investigation of microRNA-103 and microRNA-107 as
potential blood-based biomarkers for disease risk and progression of Alzheimer's disease. *J Clin Lab Anal.* Jan 2020;34(1):e23006. doi:10.1002/jcla.23006

679 91. Yilmaz SG, Erdal ME, Ozge AA, Sungur MA. Can Peripheral MicroRNA Expression Data 680 Serve as Epigenomic (Upstream) Biomarkers of Alzheimer's Disease? *OMICS*. Aug 681 2016;20(8):456-61. doi:10.1089/omi.2016.0099

682 92. Wang WX, Rajeev BW, Stromberg AJ, et al. The expression of microRNA miR-107 683 decreases early in Alzheimer's disease and may accelerate disease progression through 684 regulation of beta-site amyloid precursor protein-cleaving enzyme 1. *J Neurosci*. Jan 30 685 2008;28(5):1213-23. doi:10.1523/JNEUROSCI.5065-07.2008

bindberg RL, Hoffmann F, Mehling M, Kuhle J, Kappos L. Altered expression of miR-17bin CD4+ lymphocytes of relapsing-remitting multiple sclerosis patients. *Eur J Immunol*. Mar
2010;40(3):888-98. doi:10.1002/eji.200940032

94. Yang D, Wang WZ, Zhang XM, et al. MicroRNA expression aberration in Chinese patients
with relapsing remitting multiple sclerosis. *J Mol Neurosci*. Jan 2014;52(1):131-7.
doi:10.1007/s12031-013-0138-x

Honardoost MA, Kiani-Esfahani A, Ghaedi K, Etemadifar M, Salehi M. miR-326 and miR26a, two potential markers for diagnosis of relapse and remission phases in patient with relapsingremitting multiple sclerosis. *Gene*. Jul 10 2014;544(2):128-33. doi:10.1016/j.gene.2014.04.069

695 96. Niwald M, Migdalska-Sek M, Brzezianska-Lasota E, Miller E. Evaluation of Selected 696 MicroRNAs Expression in Remission Phase of Multiple Sclerosis and Their Potential Link to 697 Cognition, Depression, and Disability. *J Mol Neurosci*. Dec 2017;63(3-4):275-282. 698 doi:10.1007/s12031-017-0977-y

699 97. Regev K, Healy BC, Paul A, et al. Identification of MS-specific serum miRNAs in an
700 international multicenter study. *Neurol Neuroimmunol Neuroinflamm*. Sep 2018;5(5):e491.
701 doi:10.1212/NXI.00000000000491

98. Sharaf-Eldin WE, Kishk NA, Gad YZ, et al. Extracellular miR-145, miR-223 and miR-326
expression signature allow for differential diagnosis of immune-mediated neuroinflammatory
diseases. *J Neurol Sci*. Dec 15 2017;383:188-198. doi:10.1016/j.jns.2017.11.014

99. Baulina N, Kulakova O, Kiselev I, et al. Immune-related miRNA expression patterns in
 peripheral blood mononuclear cells differ in multiple sclerosis relapse and remission. J
 Neuroimmunol. Apr 15 2018;317:67-76. doi:10.1016/j.jneuroim.2018.01.005

100. Dolati S, Aghebati-Maleki L, Ahmadi M, et al. Nanocurcumin restores aberrant miRNA
 expression profile in multiple sclerosis, randomized, double-blind, placebo-controlled trial. *J Cell Physiol.* Jul 2018;233(7):5222-5230. doi:10.1002/jcp.26301

101. Regev K, Healy BC, Khalid F, et al. Association Between Serum MicroRNAs and Magnetic
Resonance Imaging Measures of Multiple Sclerosis Severity. *JAMA Neurol*. Mar 1
2017;74(3):275-285. doi:10.1001/jamaneurol.2016.5197

714 Main figures and tables















Figure 3: The contribution of individual miRNAs to the predictor of FTD diagnosis. (A) Mean absolute SHapley Additive exPlanations (SHAP) values break down the impact of specific miRNAs on FTD disease non-linear predictor output in the held-out cohort. (B) Illustration of the relationship between the miRNA levels (low – blue to high – red), SHAP values and the impact on the prediction in the held-out cohort. Positive or negative SHAP value lead the model to a more likely FTD or healthy control predictions, respectively.



miRNA levels

747

Figure 4. Distribution of the top 13 miRNA predictors in patients with FTD and controls. Box plots with complement <u>scatter</u> plots of the 13 miRNA features predicting FTD, depicting expression values of all cohort along with distribution of each miRNA. Blue dots represent the levels of a given miRNA measured in healthy control participants. Red dots represent the levels of a given miRNA measured in patients with FTD. Box – two central data quartiles, with a line at the median (Q2). Whiskers extend to show the rest of the distribution, except for points that are determined to be outliers using a method that is a function of the inter-quartile range.





Figure 5. AUC values for different miRNA classifiers for discriminating FTD vs controls in the held out data. The classifiers were either the 13 selected in the FTD model in our data, a combination of miR-

758 34a-5p, miR-345-5p, miR-200c-3p and miR-10a-3p [from], or a combination of miR-335/let-7e, miR-99b/let-

759 7e and miR-9-3p/miR-181a [from];

	Control	FTD	
Number of subjects (% males)	125 (32%)	168 (65.5%)	
UCL controls	48 (45.8%)		
Queen Mary Hospital controls	77 (23.4%)		
Age at enrolment	59.5±10.2 yr.	65.8±8.1 yr.	
UCL controls	65.6±7.3 yr.		
Queen Mary Hospital controls	55.7±10.0 yr		
Age of onset (1 st reported symptoms)		60.3±8.3 yr.	
Disease duration at enrolment		5.5±3.4 yr.	
FTD clinical subtype (bvFTD/PNFA/SD/FTD-ALS/others)		81/40/28/5/14	
FTD Mutation carriers (C9ORF72/MAPT/GRN/TBK1)		18/13/13/2	
Likely FTD pathology (TDP-43/Tau)		63/18	

760 Table 1. Summary of demographic and clinical characteristics of participants suffering from FTD

and control samples. bvFTD: behavioural FTD; PNFA: progressive nonfluent aphasia; SD: semantic
 dementia. Mean±SD.

27

Predictor	Single Feature AUC
miR-423-5p	0.69
miR-125b-5p	0.67
miR-26a-5p	0.66
sex	0.66
miR-326	0.65
miR-185-5p	0.64
age	0.64
miR-629-5p	0.63
miR-484	0.62
let-7d-3p	0.62
miR-107	0.62
let-7c-5p	0.61
miR-361-5p	0.59
miR-379-5p	0.56
miR-378a-5p	0.54

- 763 Table 2. Predictive power of selected miRNA features, when used as a single predictor for FTD on
- 764 **held-out data.** Among the most predictive features are miRNAs expressed in the brain, such as miR-26a-
- 765 5p, miR-125b-5p and let-7c-5p.

766 Supplementary figure and tables



t-SNE analysis of all control subjects presenting a desperation between the groups

767 Supplementary Figure 1. t-SNE analysis of control subjects from Queen Mary Hospital (blue) and

768 **from UCL (red).** Similarity of the two control groups suggests they could have been taken from a single

distribution which is justified further by an associated Kullback–Leibler divergence value of 0.293, a

770 measure of the difference between two probability distributions.



771

772 Supplementary Figure 2. miRNA signature associated with FTD patients with predicted pathology.

MA plot of differential miRNA expression in plasma of patients with predcited TDP pathology (A; N=63) or
 Tau pathology (B; N=19) vs non-neurodegenerative healthy controls (N=125). Log 2 transformed fold

775 change (y-axis), against mean miRNA abundance (x-axis). Red: significantly changed miRNAs (adjusted

p<0.05, Wald test). Black: miRNAs showing insignificant change.



777

778 Supplementary Figure 3. Diagnosis of FTD by age, sex and 95 differentially-expressed miRNA in a 779 logistic regression model. (A) ROC curves in the training set: true positive rate (y-axis) vs. false positive 780 rate (x-axis). Mean values and variance of data from 219 samples with 3-fold cross validation. Mean AUC 781 0.91 ± 0.05. 95% CI is 0.86-0.96. (B) Performance and generalizability on held-out data revealed by a ROC 782 curve with AUC of 0.9. (C) Reliability diagram, plotting truly observed fraction of cases (upper plot, y-axis) 783 vs. predicted probability by the prediction model (upper plot, x-axis), in five probability bins, reveals a 784 sufficiently calibrated model on the held-out set. Lower plot shows the number of individuals at each of the 785 five predicted probability bins. (D) Confusion matrix showing the prediction errors on held out dataset. At a 786 probability threshold of 0.6, we observed 0.8 Negative predictive value (NPV), 0.83 Positive Predictive 787 Value (PPV/precision), 0.73 recall (sensitivity) and 0.88 specificity. In addition, 0.12 False Positive Rate is 788 obtained, over 0.2 False Omission Rate and 0.17 false discovery rate.



789

790 Supplementary Figure 4. Levels of 13 miRNA predictors in different FTD subtypes. miRNA levels for 791 PNFA (progressive nonfluent aphasia), SD (semantic dementia), behavioral FTD (bvFTD) and the following 792 subtypes: primary progressive aphasia, corticobasal syndrome, progressive supranuclear palsy and FTD 793 with motor neuron disease, commonly referred to as "Other". Box plot with two central data quartiles, with 794 a line at the median (Q2). Whiskers extend to show the rest of the distribution, except for points that are 795 determined to be outliers using a method that is a function of the inter-quartile range. Data were analyzed 796 by one-way ANOVA. Post-hoc Bonferroni was conducted only for miR-107 (C) and miR-26a-5p (F) which 797 showed significant differences in ANOVA. Significant pairwise differences in miR-107 levels were found 798 between other FTD subtypes and both bvFTD (p=0.01) and SD (p=0.02). Significant pairwise differences 799 in miR-26a were found between other FTD subtypes and both bvFTD (p=0.04) and PNFA (p=0.02).



800

Supplementary Figure 5. Levels of 13 miRNA predictors in mutations carriers. miRNA levels for FTD patients without known FTD mutations, or with mutations in C9ORF72, Progranulin (GRN), Tau (MAPT) and TBK1. Box plot with two central data quartiles, with a line at the median (Q2). Whiskers extend to show the rest of the distribution, except for points that are determined to be outliers using a method that is a function of the inter-quartile range. Data were analyzed by one-way ANOVA.

	Before Exclusion				After Exclusion		
Group Name	Age [95% CI]	Sex	Mean Age	Group Size	Age [95% Cl]	Mean Age	Group Size
controls total (n=158)	53.8±14.5, 95% Cl [51.5, 56.1]	F	54.0	103	59.5±10.2, 95% Cl [57.7, 61.3]	58.4	85
		м	53.4	55		61.7	40
UCL controls (n=56)	61.0± 13.3, 95% Cl [57.4, 64.5]	F	61.1	30	65.55± 7.3, 95% Cl [63.4, 67.7]	65.6	26
		м	60.8	26		65.5	22
Queen Mary Hospital controls (n=102)	49.9 <u>±</u> 13.7, 95% Cl [47.2, 52.6]	F	51.1	73	55.7 <u>+</u> 10.0, 95% Cl [53.4, 58.0]	55.3	59
		м	46.8	29		57.0	18
FTD cases (n=169)	65.6 <u>+</u> 8.3, 95% CI [64.4, 67.0] M	F	66.8	59	65.8 <u>±</u> 8.1, 95% Cl [64.6, 67.0]	67.4	58
		м	65.0	110		65.0	110

806 **Supplementary Table 1.** Age and sex characteristics of the cohort and exclusion by age of 34 individuals

807 that were below 40 years of age during blood collection.